Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Febrile Neutropenia AND Fever

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Febrile Neutropenia AND Fever. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005402-53 Sponsor Protocol Number: 2-2-6 STUDY Start Date*: 2008-01-09
    Sponsor Name:Academisch Ziekenhuis Maastricht
    Full Title: Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia
    Medical condition: Prophylaxis of febrile neutropenia during chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016288 Febrile neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003166-14 Sponsor Protocol Number: RGB-02-101 Start Date*: 2013-11-20
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia.
    Medical condition: Neutropenia and febrile neutropenia in patients being treated with cytotoxic chemotherapy for malignancy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    16.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002388-33 Sponsor Protocol Number: ZKSJ0086 Start Date*: 2016-09-05
    Sponsor Name:Friedrich-Schiller-University Jena
    Full Title: Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy
    Medical condition: Patients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactam
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000087-34 Sponsor Protocol Number: XM22-08 Start Date*: 2015-06-05
    Sponsor Name:Merckle GmbH
    Full Title: An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg B...
    Medical condition: Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) CZ (Completed) BG (Completed) DE (Ongoing) ES (Completed) RO (Completed) PL (Completed) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005034-36 Sponsor Protocol Number: KWI-300-104 Start Date*: 2008-07-15
    Sponsor Name:Apotex Inc.
    Full Title: A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016288 Febrile neutropenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000266-64 Sponsor Protocol Number: PEGF/USV/P3/003 Start Date*: 2015-06-18
    Sponsor Name:USV Limited
    Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa...
    Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000775-32 Sponsor Protocol Number: AB.OH.2018 Start Date*: 2018-06-05
    Sponsor Name:Vall d'Hebron Institut de Recerca
    Full Title: Phase IV, randomized, open, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in febrile neutropenic Oncohematological Paediatric patients.
    Medical condition: Febrile neutrophenia in oncohematological pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005152-34 Sponsor Protocol Number: HOWLONG Start Date*: 2012-03-26
    Sponsor Name:José Miguel Cisneros Herreros
    Full Title: Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia
    Medical condition: In-hospital adult patients diagnosed with acute leukemia, lymphoproliferative syndrome, multiple myeloma, myelodysplastic syndrome, aplastic anemia or who have received autologous or allogeneic tra...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    14.0 10042613 - Surgical and medical procedures 10066156 Empiric treatment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010700-28 Sponsor Protocol Number: UniKoeln-478 Start Date*: 2012-03-21
    Sponsor Name:University of Cologne
    Full Title: GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia
    Medical condition: Febrile neutropenia due to chemotherapy for the following diseases: C92.0- - Acute myeloid leukemia C91.0- - Acute lymphoblastic leukemia C92.1- - Chronic myeloid leukemia C91.1- - Chronic lymphobl...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004419-11 Sponsor Protocol Number: SC35 Start Date*: 2017-04-20
    Sponsor Name:Radboud university medical center
    Full Title: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem c...
    Medical condition: Mucositis and febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10028127 Mucositis LLT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001476-37 Sponsor Protocol Number: HUB-INF-BEATLE-403 Start Date*: 2019-04-24
    Sponsor Name:Dra. Carlota Gudiol González. Servicio de Enfermedades Infecciosas. Hospital Universitari de Bellvitge.
    Full Title: Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in hematologic patients (BEATLE study).
    Medical condition: Febrile neutropenia is the presence of fever in compramised immune activity in patients with hematologic disease. In which case, an antibiotic must be started.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029357 Neutropenia malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002678-21 Sponsor Protocol Number: APO-Peg-03 Start Date*: 2012-01-10
    Sponsor Name:Apotex Inc
    Full Title: A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREA...
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003159-13 Sponsor Protocol Number: ACACIA Start Date*: 2020-09-15
    Sponsor Name:CHU DE POITIERS
    Full Title: Amoxicillin-clavulanate alone or in combination with Ciprofloxacin in Low-Risk Febrile Neutropenic adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III C...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000533-36 Sponsor Protocol Number: GETH-PRODORI-2011-01 Start Date*: 2011-06-28
    Sponsor Name:Grupo Español de Trasplante Hematopoyético (GETH)
    Full Title: Estudio prospectivo, abierto, multicéntrico, de brazo único para evaluar la farmacocinética/farmacodinamia, factibilidad y seguridad de Doripenem como monoterapia en infusión prolongada (1000 mg en...
    Medical condition: Tratamiento empírico de la neutropenia febril
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003553-15 Sponsor Protocol Number: GC-627-05 Start Date*: 2018-06-22
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage I-III breast cancer and are scheduled to undergo chemotherapy. This is a prophylaxis for myleotoxic chemotherapy induced ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-005046-10 Sponsor Protocol Number: HEMSC42 Start Date*: 2019-07-23
    Sponsor Name:Radboud university medical center
    Full Title: Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic s...
    Medical condition: Febrile neutropenia and mucositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10028127 Mucositis LLT
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004281-10 Sponsor Protocol Number: PT/11/2017 Start Date*: 2018-01-10
    Sponsor Name:Department of Pediatric oncology, Aarhus University hospital
    Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia
    Medical condition: Pediatric oncology patients with fever
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10051312 Neutropenic fever LLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004628-23 Sponsor Protocol Number: M000507_6004 Start Date*: 2015-03-17
    Sponsor Name:Sanofi
    Full Title: Comparison of Teicoplanin and Vancomycin in Terms of Efficacy and Side Effect Profile During Initial Antibiotic Treatment of Febrile Neutropenic Patients at High Risk For Gram-Positive Infection: M...
    Medical condition: Neutropenic and febrile patients with hematological or solid tumors, who are at high risk for gram-positive bacterial infection.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005030-54 Sponsor Protocol Number: MK-0991-042 Start Date*: 2015-02-24
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 2...
    Medical condition: Neutropenic immunosuppressed
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 14:58:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA